Adc Therapeutics Sa (ADCT) financials
Adc Therapeutics Sa revenue and earnings by year
Adc Therapeutics Sa's revenue was $81.4 million in the fiscal year to December 31, 2025, up 14.9% from the year before. Net income was -$143 million, -175.3% of revenue. Since the fiscal year to December 31, 2018, revenue has grown 84.0% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 7 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 81 | 71 | 70 | 210 | 34 | 2 | 1 |
| Revenue growth | 14.9% | 1.8% | -66.9% | 518.9% | 1349.4% | 105.3% | — |
| Gross profit | 76 | 65 | 67 | 207 | 33 | — | — |
| Gross margin | 92.9% | 91.6% | 96.4% | 98.4% | 95.9% | — | — |
| Operating income | -121 | -131 | -166 | -123 | -262 | -119 | -126 |
| Operating margin | -149.3% | -184.4% | -238.6% | -58.8% | -771.6% | -5102.5% | -11047.5% |
| Net income | -143 | -158 | -240 | -157 | -230 | -116 | -123 |
| Net margin | -175.3% | -222.8% | -345.1% | -74.9% | -678.2% | -4977.9% | -10797.9% |
| Diluted EPS | -$1.12 | -$1.62 | -$2.94 | -$2.02 | -$3.00 | — | — |
| Free cash flow | -142 | -125 | -122 | -139 | -231 | -123 | -123 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ADCT in Markets.
See also: ADCT returns
No forecast, no recommendation. This page describes Adc Therapeutics Sa from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.